|
| Brand Name: | LIBANG |
| Model Number: | USP |
| MOQ: | 1KG |
| Price: | FOB USD 150-500/KG |
| Payment Terms: | T/T |
| Supply Ability: | 2MT/MONTH |
Diatrizoate Meglumine
Diatrizoate meglumine injection is used to help diagnose or find problems in the urinary bladder. It is a radiopaque contrast agent. Contrast agents are used to create a clear picture of the different parts of the body during certain medical procedures, such as retrograde cystourethrography.
Diatrizoate Meglumine is the meglumine salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. The iodine moiety of diatrizoate meglumine is not penetrable by X-rays, therefore blocks the X-ray film exposure by radiation. This makes it possible to distinguish on X-ray film, body parts that contain diatrizoate meglumine from body parts that do not contain this agent and allows for visualization of different body structures.
| TEST | SPECIFICATION | RESULT |
| Appearance | White, odorless powder | Conforms |
| Identification | (1) It responds to the Thin-Layer Chromatographic Identification Test | Conforms |
| (2) Positive reaction | Conforms | |
| Water | 4.5%~7.0% | 5.6% |
| Residue on ignition | NMT0.1% | 0.06% |
| Iodine and iodide | NMT 0.02% of iodide |
Conforms |
| Heavy metals | NMT 0.002% | Conforms |
| Free aromatic amine | NMT 0.05% | 0.008% |
| Ethyl alcohol | NMT 0.5% | Not detected |
| Acetic acid | NMT 0.5% | Not detected |
| Bacterial endotoxins | NMT 1.5 EU/g | ＜1.5 EU/g |
| Microbial Limit | Total aerobic microbial count: ＜1000 cfu/g | Conforms |
| Total yeast and molds count: ＜100 cfu/g | Conforms | |
| Assay | 98.0%～102.0%(Calculated on the anhydrous basis) | 99.2% |
Who we are:
XI’AN LIBANG PHARMACEUTICAL CO.,LTD. founded in 1996 with a location in Xi’an City of China, the center of the northwest pharmaceutical industry, is specialized in research, development, production and distribution of specialty pharmaceutical products. As the first and also largest supplier of generic Propofol in China, LIBANG started its business and subsequently launched a broad portfolio finished dosage forms covering s, cardiovascular, antineoplastic, clinical nutrition etc.
With more than 20 years growth, LIBANG has transformed into an integrated health care solution provider, LIBANG HEALTHCARE GROUP, with diversified fields covering high value-added APIs, pharmaceutical excipients, prescription drugs, OTC products, biomedicine, medical devices.
LIBANG is a technology-driven firm, with more than 8% of the annual sales revenues devoted to research and innovation, establishing a unique R&D platform to proactively follow the latest pharmaceutical technology frontier.
LIBANG now is one of Top 100 China’s Pharmaceutical Industries and also listed in the Top 20 The Most Potential Chinese Pharmaceuticals that was rated by the IMS Health.
